Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. What Is Return On Capital Employed (ROCE)? Just to clarify if you're unsure ...

Earnings Report 1.110 USD Q4 2021 Earnings Release 01/26/2022 Indices Commodities Currencies Stocks ...

Analysts see big upside for these undervalued health care stocks.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant ... Also, a next-generation diagnostic system, ARCHITECT, had been launched. Throughout the 2000s ...

Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had ...

2024 Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.

Abbott Laboratories and Reckitt Benckiser shares surged on Friday after a Missouri court ruled in the two companies’ favor in a dispute over claims their specialist infant formulas had caused a ...

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:ABT), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of $133.00. The company’s shares closed yesterday at ...